Time Is Vision in nAMD and RVO
An NEI Blindness
Prevention Initiative
in nAMD and RVO
“We must be proactive through regular screening, prompt referral to specialists, and early treatment, so we can minimize the effects of age-related macular degeneration and retinal vein occlusion.”
— Julia Haller, MD
Past President of the American Society of Retina Specialists
Chairman, Wills Eye Hospital
Helping your patients' eyesight through education: Find out more.
Resources
PATIENT RESOURCES
AGE-RELATED
MACULAR DEGENERATION
- AAO Age-Related Macular Degeneration Preferred Practice Pattern ® ▶
-
Visual acuity of patients with nAMD at the time
of diagnosis ▶ -
Anti-VEGF utilization in nAMD within 12 months
of diagnosis ▶ -
Long-term outcomes of anti-VEGF therapy
in nAMD ▶ -
CATT Trial: Ranibizumab and Bevacizumab
for Neovascular Age-Related Macular Degeneration ▶ - Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies ▶
RETINAL VEIN OCCLUSION
- AAO Retinal Vein Occlusions Preferred Practice Pattern ® ▶
- CRUISE: Efficacy of early anti-VEGF treatment for macular edema after CRVO ▶
- Benefits of early anti-VEGF therapy in RVO presenting with poor VA ▶
-
Reducing retinal nonperfusion with anti-VEGF
in RVO ▶ - RETAIN: Long-term outcomes of anti-VEGF therapy in RVO ▶
- SCORE2: Switching anti-VEGF treatment in poor responders with macular edema secondary to CRVO/HRVO ▶